Common stock, par value $0.01 per share
- Symbol
- WAT
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Waters Corp
WATNYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On November 3, 2026, Waters Corporation announced its results of operations for the quarter ended October 3, 2026. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K.…
Press release in this filing
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results →Company context
Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~15,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.
Current securities
Registered securities in this filing
WATERS CORP /DE/ · 8-K · Filed 2026-11-03
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition
On November 3, 2026, Waters Corporation announced its results of operations for the quarter ended October 3, 2026. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 For Immediate Release Contact: Caspar Tudor, Head of Investor Relations - (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by organic revenue growth of 9% as reported and 10% in constant currency, with acquired business revenue landing slightly ahead of guidance. GAAP EPS of $0.82; Adjusted EPS of $4.10 grew 21% and exceeded guidance. Analytical Sciences Division (ASD) grew 8% as reported and 9% in constant currency, led by double-digit instrument and chemistry growth from strong execution, new product innovation, and rising customer testing volume. In the Biosciences Division (WBD), reagents grew high single-digits on a prior year comparable basis, reflecting a 400bps acceleration in year-over-year growth, as research and clinical reagents both grew high single-digits; In the Advanced Diagnostics Division (ADx), microbiology grew mid-single-digits on a prior year comparable basis. The Company is raising every…
Open exhibit ↗